Australasian Journal of Dermatology最新文献

{"title":"Childhood eczema prevalence in New Zealand using topical corticosteroid dispensing data","authors":"Georgina Harvey MBBS, MHSc, FACD, FRACP,&nbsp;Diana J. Purvis MBChB, FRACP, FNZDSI,&nbsp;John M. D. Thompson BSc, MSc(Hons), PhD,&nbsp;Libby Haskell NP, MN, PhD,&nbsp;Harriet Kennedy BHB, MBChB, MPhil, FRACP,&nbsp;Karen Hoare NP, PhD,&nbsp;Stuart R. Dalziel FRACP, PhD","doi":"10.1111/ajd.14347","DOIUrl":"10.1111/ajd.14347","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To determine the prevalence of eczema among children in New Zealand.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Population-based retrospective observational study utilising national pharmaceutical dispensing records for topical corticosteroids and emollients for all New Zealand children aged 0–14 years from 1st January 2006 to 31st December 2019. Data are reported using descriptive statistics, with comparisons between ethnicities and socioeconomic quintiles undertaken with rate ratios.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Based on dispensing data, the prevalence of eczema for New Zealand children aged 0–14 years in 2018 was 14.0% (95% CI 14.0%–14.1%), with prevalence decreasing in older age groups (children aged &lt;1 year 26.0% (25.6%–26.4%); children aged 10–14 years 8.8% (8.7%–8.9%)). Prevalence was higher in Pacific children (23.6% (23.3%–24.0%)), but slightly lower in Māori children (13.2% (13.0%–13.3%)).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Eczema is a common condition affecting a considerable proportion of children in New Zealand. This study provides nationwide paediatric prevalence data for New Zealand, and highlights the increased burden of eczema in Pacific children. Inequity in dispensing of topical corticosteroids is postulated to explain the reduced rates found for Māori children compared to previous studies. These results support the need for further research to determine factors contributing to differing eczema prevalence rates in New Zealand.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 7","pages":"576-584"},"PeriodicalIF":2.2,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anetoderma as an initial presentation of leprosy in a patient with prolonged steroid use","authors":"Roberto Fernandes Soares-Neto MD,&nbsp;Antônio Roberto de Oliveira Ramalho MD,&nbsp;Martha Débora Lira Tenório MD,&nbsp;Jonnia Maria Sherlock Araújo PhD,&nbsp;Lana Luiza da Cruz Silva PhD,&nbsp;Pedro Dantas Oliveira PhD,&nbsp;Paulo Ricardo Martins-Filho PhD,&nbsp;Fedro Menezes Portugal MD","doi":"10.1111/ajd.14348","DOIUrl":"10.1111/ajd.14348","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 7","pages":"e215-e218"},"PeriodicalIF":2.2,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141578882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vulvovaginal lichen planus mimicking desquamative inflammatory vulvovaginitis: A case series","authors":"Marlene Wijaya BMed, MD, MPhil,&nbsp;Rebecca Bronwyn Saunderson BMedSci (hon1), MBBS (hon), MPhil (Cantab), FACD,&nbsp;Gayle Fischer MBBS (hon1), MD, FACD","doi":"10.1111/ajd.14344","DOIUrl":"10.1111/ajd.14344","url":null,"abstract":"&lt;p&gt;Vulvovaginal lichen planus (VLP) is a chronic inflammatory dermatosis of the vulva with or without vaginal involvement. Its diagnosis can be challenging due to variations in morphology and histopathological findings. In 1988, Edwards and Friedrich reported a case series of VLP patients whose clinical presentation mimicked desquamative inflammatory vulvovaginitis (DIV).&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; DIV is an uncommon non-infective vulvovaginitis, characterised by pain, dyspareunia, pruritus and white or green non-offensive discharge. However, unlike VLP is not a scarring condition.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Herein we present a case series of women who were initially diagnosed with DIV but did not respond to treatment with topical clindamycin which is usually highly effective (Table 1). When their diagnosis was revised, they improved following treatment appropriate for VLP.&lt;/p&gt;&lt;p&gt;To our knowledge, this is the only other case series since 1988 to report patients with DIV-like VLP. DIV and VLP can pose significant diagnostic challenges as both have a wide range of clinical manifestations and histopathological findings, which often overlap. On histology, lichenoid infiltrate can be found in either condition, and the observed changes are often reported as ‘non-specific’. Additionally, the two conditions have a predilection for peri-/post-menopausal women.&lt;span&gt;&lt;sup&gt;3, 4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Desquamative inflammatory vulvovaginitis is typically characterised by vulval pain, dyspareunia and purulent white or green non-offensive discharge.&lt;span&gt;&lt;sup&gt;5, 6&lt;/sup&gt;&lt;/span&gt; Erythema and petechiae or punctate erosions are usually observed on examination.&lt;span&gt;&lt;sup&gt;2, 3&lt;/sup&gt;&lt;/span&gt; Meanwhile, in VLP, purulent discharge is not normally observed. DIV does not result in scarring, whereas VLP typically presents with glazed erythema, erosions and hyperkeratosis and frequently, if untreated causes scarring, loss of vulval structure and stenosis of the vagina.&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt; There can also be associated oral mucosal involvement (oral lichen planus) which is not observed in DIV. In our case series, petechiae were consistently observed in all patients. This suggests that although petechiae are not common findings in VLP,&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; these may re-present a small sub-type of VLP mimicking DIV. Additionally, as in case 3, oral mucosal involvement may provide an additional clue pointing to a diagnosis of VLP.&lt;/p&gt;&lt;p&gt;Treatment resistance should also prompt clinicians to consider an alternative diagnosis, as DIV usually responds promptly to topical antibiotic treatments, particularly 2% clindamycin. A study by Bradford et al. compared 101 cases of DIV to 75 cases of VLP.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; The majority of DIV patients (94%) were responsive to 4–6 weeks of intravaginal clindamycin 2%, with 35% requiring maintenance therapy. In another study by Sobel et al. of 130 DIV patients over a 12-year period, 86% of the patients reported significant symptom improvem","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 7","pages":"e203-e207"},"PeriodicalIF":2.2,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.14344","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141496961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapy of pemphigus foliaceous with prominent neutrophilic pustules with Acitretin: A case report and literature review","authors":"Wenjie Li MD,&nbsp;Zhongyun Deng MD,&nbsp;Ge Yang MD,&nbsp;Wei Liu MD,&nbsp;Zhen Rang MD,&nbsp;Tingting Wang MD,PhD,&nbsp;Mi Wang MD,&nbsp;Fan Cui MD,PhD","doi":"10.1111/ajd.14346","DOIUrl":"10.1111/ajd.14346","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 7","pages":"e211-e214"},"PeriodicalIF":2.2,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141496960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and dermoscopic features of onychomatricoma in Korean patients","authors":"Min Jae Kim MD,&nbsp;Bo Ri Kim MD, PhD,&nbsp;Ji Su Lee MD, PhD,&nbsp;Je-Ho Mun MD, PhD","doi":"10.1111/ajd.14332","DOIUrl":"10.1111/ajd.14332","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 5","pages":"e117-e120"},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141465879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of serial QuantiFERON-TB Gold in tube test results and tuberculosis infection status in patients with psoriasis receiving anti-IL-17 treatment (secukinumab and ixekizumab): Real-world data from a tuberculosis-endemic country","authors":"Ece Erbağcı MD,&nbsp;Sema Koç Yıldırım MD,&nbsp;Fatma Aslı Hapa MD","doi":"10.1111/ajd.14340","DOIUrl":"10.1111/ajd.14340","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In comparison with TNF-α inhibitors, anti-IL-17A agents are considered to have a lower risk of active tuberculosis (TB) or latent TB infection (LTBI) reactivation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this study, we aimed to evaluate the TB infection status and serial QuantiFERON-TB-Gold in tube test (QFT) results of psoriasis patients using IL-17 inhibitors (secukinumab [SEC] and ixekizumab [IXE]) in a real-world setting from a tuberculosis-endemic country. Patients who used an anti-IL-17 agent for at least 3 months in our follow-up were included in the study. Patients' clinical and demographic features, baseline QFT results and latest QFT results (if any), and TB infection status were noted from the past medical records.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 717 patients, of whom 333 (46.4%) were female, were included in the study. The cumulative exposure time to an anti-IL-17 agent was 14,147 patient-months, 9743 patient-months for SEC and 4404 patient-months for IXE. Also, 459 (SEC = 305/IXE = 154) patients used an anti-IL-17 agent for ≥ 12 months. Of these, 125 had positive baseline QFT results. In all, 334 had negative baseline QFT results. The latest QFT result of 309 was also negative (persistent seronegative group). During follow-up, the QFT results of 10 patients changed from negative to positive (positive seroconversion group). Seven of them were using SEC and three were using IXE, respectively. No case of active TB infection was detected.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In our study, the positive seroconversion rate of 10/334 seems high, but this did not translate to active disease. However, closer monitoring may be required, especially in patients with advanced age, the presence of PsA, long disease duration and long anti-IL-17 treatment duration.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 7","pages":"567-575"},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.14340","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141465880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to adalimumab in Caucasian and Asian patients with hidradenitis suppurativa: A retrospective cohort study of an Australian cohort stratified by patient-reported ethnicity","authors":"James Pham MD,&nbsp;Akshay Flora MD, MRes,&nbsp;Lauren Guttman MD Candidate,&nbsp;Timothy Allan MD Candidate,&nbsp;Nisha Suyien Chandran MBBS, MRCP,&nbsp;John W. Frew MBBS, MMed, MS, PhD","doi":"10.1111/ajd.14343","DOIUrl":"10.1111/ajd.14343","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background/Objectives</h3>\u0000 \u0000 <p>Caucasian and Asian patients with hidradenitis suppurativa demonstrate significant differences with regard to age, gender and body mass index. Demographic characteristics are known to influence the efficacy and drug survival of hidradenitis suppurativa therapeutics including biologic therapies. What remains unknown is the impact of ethnicity upon the efficacy of therapeutics once demographic and disease characteristics have been taken into account. This is an important question given the expansion of biologic therapies for HS into the global patient community.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We assessed 170 patients from a single HS specialist centre in Australia stratified by patient-identified ethnicity including those identifying as either Caucasian or Asian.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Asian patients demonstrated lower BMI, higher rates of smoking and greater odds of Hurley stage 3 disease with tunnels than Caucasian patients in line with the reported literature. There was no significant difference between percentage of individuals achieving HiSCR50 or IHS4-55 at Week 16. Significant differences were seen in median time to secondary loss of response, and Kaplan–Meier curve analysis showed a significant difference between curves when stratified by patient-reported ethnicity. Cox regression analysis demonstrated after accounting for age, gender, BMI, smoking and Hurley stage, the significance of ethnicity in influencing time to secondary loss of response disappears.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Caucasian or Asian ethnicity does not influence response to adalimumab treatment on patients with hidradenitis suppurativa.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 7","pages":"560-566"},"PeriodicalIF":2.2,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.14343","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience of dermatologic biologic therapy use and associated opportunistic infection management in Australia's tropical north","authors":"Lucinda Adams MBBS,&nbsp;Cyrille Metin NP,&nbsp;Annabel Stevenson MBBS, MMed, FACD","doi":"10.1111/ajd.14315","DOIUrl":"10.1111/ajd.14315","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background/Objectives</h3>\u0000 \u0000 <p>Royal Darwin Hospital (RDH) is the sole public dermatology service in the Northern Territory (NT). Prescription of biologic therapies (BT) in the NT is uniquely challenging, with remote populations carrying a high tropical disease burden. The aim of this audit is to examine the demographics and outcomes of patients on BT for dermatologic conditions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Retrospective case note review of patients receiving BT through the RDH Dermatology department between August 2021 and October 2023. Data analysed were demographics, location, dermatological diagnosis and serology status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In this audit, 115 patients were included. Age range of 13–91 years, mean of 51.1 years (±14.7), 52 (45.2%) patients were female and 8 (7.8%) identified as First Nations Australian. A large geographical area was serviced, with a primary address between 1 and 1496 km from RDH. Eighteen patients (15.7%) have discontinued BT completely. There was a statistically significant relationship between cessation of BT and increased distance of primary residence from RDH (<i>p</i> &lt; 0.0007). Eighteen patients (15.7%) required management of infections identified in opportunistic infection screening. These infections were strongyloidiasis, tuberculosis, melioidosis and hepatitis B.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>There is significant anxiety surrounding BT and tropical infections, including in returning travellers in southern Australian states. There has been particular interest in strongyloidiasis infection, as dupilumab acts on the Th2 immunity mechanism critical to parasitic infection response. This audit exhibits the unique experience of dermatological care in a tropical setting, demonstrating how BT can be used safely and how, when identified, these tropical infections can be successfully managed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 5","pages":"462-466"},"PeriodicalIF":2.2,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beta-blockers for the treatment of infantile haemangiomas in premature infants","authors":"Lynn Chua Ting Ling MD,&nbsp;Mark Koh Jean Aan MD","doi":"10.1111/ajd.14338","DOIUrl":"10.1111/ajd.14338","url":null,"abstract":"<p>Beta-blockers have been established as a treatment of infantile haemangiomas (IH) since its serendipitous discovery for use in IH in 2008. However, data on the safety of these beta-blockers for use in IH in preterm infants are scarce. A retrospective study was performed to review the safety of oral propranolol and topical timolol in the treatment of IH in a cohort of preterm infants treated at our tertiary paediatric hospital. It was observed that there was an increased risk of adverse events amongst the preterm infants with chronic lung disease, retinopathy of prematurity and gastroesophageal reflux, when treated with oral propranolol.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 7","pages":"e194-e197"},"PeriodicalIF":2.2,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Technostress: The impact of technology on Italian dermatologists' burnout","authors":"Vincenzo Picone MD,&nbsp;Cataldo Patruno,&nbsp;Vincenzo Greco,&nbsp;Alessia Spignese,&nbsp;Luigi Coronella,&nbsp;Maddalena Napolitano","doi":"10.1111/ajd.14341","DOIUrl":"10.1111/ajd.14341","url":null,"abstract":"<p>Dermatologists' burnout is a growing phenomenon. During the last years, an important role on medical stress is played by the ever-increasing use of common technological devices (smartphones, smartwatches, PCs and tablets). The aim of the study was to investigate whether digital technology use causes burnout among Italian dermatologists, using a survey conducted among a group of Italian dermatologists. The final sample contained 194 responses valid for analysis. A positive and significant relationship between technostress, assessed through Technostress Inventory and burnout, assessed through Maslach Burnout Inventory, among Italian dermatologists was found. Our data seems suggesting a close relationship between technostress and dermatologist burnout.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"65 7","pages":"585-587"},"PeriodicalIF":2.2,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}